Matinas BioPharma Holdings, Inc. received a deficiency letter from the NYSE American indicating non-compliance with listing standards due to low stock price, but it does not immediately affect the trading of the company's common stock.
AI Assistant
MATINAS BIOPHARMA HOLDINGS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.